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Abstract
Hepatocellular carcinoma (HCC) is the fifth most frequent cancer worldwide with high morbidity, mortality and increasing
incidence. It is of note that the main curative therapies for HCC are hepatic resection and transplantation although the
majority of patients at the time of presentation are not eligible for resection or orthotopic liver transplantation (OLT) due
to the underlying cirrhosis. Currently, a variety of loco-regional therapies, including radiofrequency ablation (RFA),
percutaneous ethanol injection (PEI), microwave coagulation therapy (MCT), transarterial chemoembolization
(TACE) and others, have been developed as alternative treatment options for HCC. Among these techniques, RFA
is currently the most widely used treatment, due to its several advantages, such as safety and efficacy. To date, the
effectiveness of RFA for HCC is reduced by the presence of residual tumor as a consequence of insufficient treatment.
In order to ameliorate the effects of RFA on HCC, several in vivo studies, have been performed on its application as
single or in combination treatment with drugs or others loco-regional therapies, by using rabbit VX2 liver model. This
represents an ideal model of liver cancers and is widely used for imaging and other experimental studies due to the
rapid growth of these tumors and their similarity to human hepatocellular carcinoma. In order to elucidate the
therapeutic potential of RFA with adjuvant treatments for HCC, we reviewed the latest findings on the RFA-based
studies in rabbit VX2 hepatocarcinoma models.
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Background
HCC is still one of the most important diseases for health
care systems due to its high mortality, morbidity, and in-
creasing incidence worldwide [1, 2]. It is of note that the
main curative therapies for HCC are hepatic resection and
transplantation although the majority of patients at the
time of presentation are not eligible for resection or OLT
due to the underlying cirrhosis. Difficulties in surgical re-
section may be associated to site, size, and number of tu-
mors, vascular and extra hepatic involvement as well as the
general condition and liver function of the patients [3–6].
Only about 20 % of HCC cases are classified as resectable
[7]. Moreover, the liver is considered a site of metastasis
from other solid cancers [8–12]. To date, a variety of loco-
regional therapies, RFA, PEI, MCT, TACE and others, have
been developed as alternative treatment options for HCC
due to its benefits, such as safety, minimal invasiveness,
and efficacy [7]. It has been demonstrated that the effective-
ness of RFA for HCC was reduced by the presence of re-
sidual tumor and local recurrence after treatment, probably
due to the location of tumor around the intrahepatic vascu-
lature [13] or to the diameter of tumor. Several studies
showed that, residual tumor progression after insufficient
RFA could be associated to different reasons and molecular
mechanisms [14–18] in particular to the inflammation
process which is involved in tumor progression of different
types of cancer [19, 20]. The inflammation is induced by
thermal destruction of liver carcinoma after RFA at the
target sites, leading to progression of HCC tumor [20].
In order to ameliorate the effects of RFA on HCC and
to bypass the problem of residual tumor, several in vivo
studies have been performed on its application as single
or in combination treatment with drugs or other loco-
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The rabbit VX2 tumor model is widely used in experi-
mental oncology. It is classified as leporine anaplastic
squamous cell carcinoma being characterized by rapid
growth, hypervascularity and easy propagation in the
skeletal muscle [25–28]. This model has been applied to
various types of cancer [29–38], and recently it has been
used in doxorubicin interventional chemotherapy of
renal carcinoma [39]. The transplantation of the VX2
cells can be achieved either by injecting the tumor cell
suspensions or by implanting solid tumor pieces (fresh o
frozen) as previously described [40].
This represents an ideal model of liver cancers due to
the rapid growth of VX2 tumors and their similarity to
human hepatocellular carcinoma. Here we reviewed the
latest findings on the RFA based studies in rabbit VX2
hepatocarcinoma models, with the aim of elucidating the
therapeutic potential of RFA with adjuvant treatments
for HCC.
Generation of VX2 model for liver tumor treatment: an
overview of loco regional therapy-based studies
Several studies demonstrated that intrahepatic implant-
ation of solid tumor fragments is more successfully that
the injection of a cell suspension [41–43], although a son-
ography implantation of liver tumors achieved a good suc-
cess rate [44]. The protocol for liver implantation has
been detailed described by Parvivian et al. [40]. It is of
note that the preferred implantation site for VX2 tu-
mors is the left lateral hepatic lobe due to a more favor-
able angle of the feeding artery for later angiographic
catheterization. Our group and other researchers demon-
strated that the tumors developed after 2–4 weeks form
tissue implantation with nodules of 2-3 cm [38] (Fig. 1).
It also has been reported that the application of ultra-
sonography, is useful to following the solid tumor growth
and to detect the presence of necrosis [44]. The use of
non-necrotic tumors allows optimizing the evaluation of
tumor response to loco-regional therapy experiments. It is
largely provided that loco-regional therapies, including
RFA and TACE, play a major role in the clinical
management of hepatocellular carcinoma [45]. Regard-
ing pre-clinical studies, many evidences reported the
safety and the efficacy of different loco-regional treat-
ments in rabbit VX2 liver tumor model, especially in
combination with adjuvant substances. Gholamrezanez-
had et al., evaluated the pharmacokinetic profile (PK) and
embolization effect of 70–150-μm doxorubicin eluting
beads (DEBs) following intra-arterial injection, in the
rabbit liver VX2 tumor model [46]. In VX2 model of liver
metastases, it has been reported that HepaSphere and
DEBS microspheres loaded with irinotecan, caused signifi-
cant necrosis of tumor nodules [47]. Xia et al., showed
that intra-arterial interleukin-12 gene delivery combined
with chemoembolization, had a potent anti-tumor effect
in a VX2 rabbit HCC [48]. In another study performed
on the rabbit VX2 liver tumor model, was demonstrated
that the application of Electroporation-Mediated Trans-
catheter Arterial Chemoembolization (E-TACE) increased
liver tumor chemotherapeutic uptake following targeted
transcatheter infusion [49]. In addition, Deng et al.,
showed that TACE with arterial administration of Endo-
star (an antiangiogenic agent) inhibited the angiogenesis
biomarkers associated with TACE in a rabbit model bear-
ing VX2 liver tumor [50]. Potentiated anti-tumor effects
on liver cancer, were also observed in a similar study with
chloroquine and TACE. The authors showed that chloro-
quine, which is a traditional drug used for treatment of
malaria [51], promoted the anticancer effect of TACE in a
rabbit VX2 liver tumor model. Other studies proved that
single-bolus regional chemotherapy with doxorubicin, had
limited anti-tumor effects when compared with TACE in a
rabbit VX2 liver tumor model [52]. Very recently, it has
been reported that the elaborate integration of TACE with
nanoparticle-enhanced High-intensity focused ultrasound
(HIFU) cancer surgery, applied in VX2 liver tumor model,
could efficiently enhance the HCC cancer treatment out-
come, representing a new and efficient therapeutic proto-
col/modality for clinic cancer treatment [53]. Another
research demonstrated that Transarterial oily chemoembo-
lization (TOCE), one of the most effective approaches for
Fig. 1 VX2 tumor liver development. a Picture reveals resected hepatic tumor after 4 week from VX2 tumor pieces implant, b Tumor bisected
shows necrotic core (asterisk) and peripheral viable tumor (arrows)
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the treatment of patients with HCC, who are not suitable
for surgical therapy [54], combined with Lidamycin (LDM)
[55], shows potent therapeutic efficacy in VX2 rabbit liver
tumor model. Synergistic effects of RFA and toll like recep-
tor 9 (TRL9) stimulation result in a potentiated antitumor
T cell response and cytotoxicity in the VX2 hepatoma
tumor [23].
Taken together all these different data, summarized in
Table 1, suggest that these combined treatments may
have potential synergistic effects on liver cancer.
Radio-frequency ablation of VX2 rabbits model for HCC
treatment: experimental studies
RFA is considered one of the standard procedures for local
tumor treatment such as prostate [56, 57], kidney [56],
bone [58, 59], brain [60, 61], lung [62, 63] and liver tumors
[45, 64–67]. RFA is commonly used for the treatment of
early HCC, although recently the technique has been im-
proved to bypass the problem of burden for patients and
operators [68]. RFA is classified as thermal technique since
induces cell tumor destruction by heating tumor tissue to
high temperatures [69, 70]. It is important to underline
that the effectiveness of RFA for HCC is reduced by the
presence of residual tumor as a consequence of insufficient
treatment. It is very difficult to avoid the residual tumor
due to several causes such as the liver’s anatomy, the
mechanisms of RFA, the pathological characteristics of
HCC and the inflammation. It has been demonstrated that
despite it is possible to set the target temperature around
105–115 °C during RFA, only the tissues surrounding the
electrodes can reach that temperature due to “heat sink” ef-
fect of blood large vessels near the tumor [71].
Many evidences have demonstrated a rapid progres-
sion of residual HCC after RFA [72, 73]. In addition, this
tumor becoming very aggressive, switches to sarcoma
[74, 75] thus leading to bad prognosis for patients.
In order to ameliorate the effects of RFA on HCC and
to clarify the underlying mechanisms of rapid progres-
sion of residual tumor after insufficient RFA, several in
vivo studies, have been performed using rabbit VX2
hepatocarcinoma model. The study conducted by Ke et
al., was designed to prove whether low temperature of
RFA at the target sites, and could facilitate progression
of residual hepatic VX2 carcinoma trying to dissect the
underlying mechanisms. The VX2 nodules were trans-
planted into the liver rather than derived from the liver
itself, in order to reduce the feeding artery and the heat
sink effect. The residual VX2 hepatoma model in rabbits
was established by using RFA at different temperatures
(55, 70 and 85 °C). Actually, it is of note that different
molecular factors are involved in HCC progression and
metastasis, such as IL-6, PCNA, MMP-9, VEGF, HGF
[76–78]. The authors demonstrated that residual hepatic
VX2carcinoma facilitated its progression through indu-
cing over expression of several molecular factors, such
as PCNA, MMP-9, VEGF, HGF and IL-6 [18].
In another research, was proved that the inflammation
induced by RFA at the target sites, facilitated the pro-
gression of residual HCC tumor [21]. The authors gener-
ated the orthotropic VX2 rabbit HCC model with two
hepatic tumors in different lobes and treated the animals
with different doses of aspirin used as anti-inflammatory
drug. Results from this study demonstrated that aspirin
inhibited the inflammatory reaction of animals after
RFA, suggesting that aspirin could be potentially used as
an adjuvant therapy with RFA for treating HCC. Table 2
summirizes the effects of RFA on the progression of re-
sidual HCC in VX2 rabbit model of liver cancer.
Conclusions
Altogether these data suggest that inflammation and low
temperature of RFA at the target sites could be important
reasons for rapid progression of residual hepatic VX2
Table 1 Effects of Loco-regional treatments on tumor growth
in VX2 rabbit model of liver cancer
Animal model Treatment Effects on tumor Reference
Rabbit Vx2 liver
tumor model
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Abbreviations: TACE transcatheter arterial chemoembolization, IL-12
interleukin-12, LDM Lidamycin, TOCE transarterial oily chemoembolization, HIFU
high-intensity focused ultrasound, TRL9 toll like receptor 9
Table 2 Effects of RFA on the progression of residual HCC in
VX2 rabbit model of liver cancer
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carcinoma. Future studies will be needed to validate the
therapeutic potential of drugs or other loco-regional tech-
niques as an adjuvant therapy with RFA for treating HCC.
Abbreviations
(E-TACE), Electroporation-Mediated Transcatheter Arterial Chemoembolization;
(HIFU), high-intensity focused ultrasound; DEBs, doxorubicin eluting beads; HCC,
hepatocellular carcinoma; HGF, hepatocyte growth factor; IL-6, Interleukin-6; LDM,
lidamycin; MCT, microwave coagulation therapy; MDR, multidrug
resistance; MMP-9, matrix metallopeptidase 9; OLT, orthotopic liver
transplantation; PCNA, Proliferating cell nuclear antigen; PEI, percutaneous
ethanol injection; PK, pharmacokinetic profile; RFA, radiofrequency ablation;
TACE, transcatheter arterial chemoembolization; TOCE, transarterial oily
chemoembolization; TRL9, toll like receptor 9; VEGF, Vascular endothelial
growth factor
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